News

Bland also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott. Bland received his B.S. and his M.B.A.

Under this agreement, Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467. This peptide therapeutic has completed an initial clinical study

MacuCLEAR is developing MC 1101 for the treatment and prevention of the progression of age related macular degeneration (AMD). Mystic Pharmaceuticals said that it has developed a novel

The letter outlined questions that the FDA identified during its review of the new drug application (NDA) for over-the-counter (OTC) Zegerid. Santarus said that it is in regular

Under the terms of the option agreement, Cephalon will pay Ception a $100 million upfront option payment. Ception’s lead product is reslizumab. Reslizumab is a humanized monoclonal antibody

Xenazine is the first and only FDA-approved treatment specifically developed for any Huntington’s disease-related symptom, the company said. Paul Dreyer, president of S&R, said: “In recent months, the

In this role, Mr Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for

The transaction was structured as an asset purchase under which AngioDynamics will pay $1.75 million in cash for the assets of the business plus a contingent payment based

Cleared for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff assay targets the toxin B gene, found in virtually all toxigenic Clostridium